Is Nature's Sunshine Products, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 26, which is significantly higher than the peer average of 21.11 for companies like Chromadex Corp. and USANA Health Sciences, Inc., which have P/E ratios of 39.82 and 16.23, respectively. Additionally, the EV to EBITDA ratio of 5.08 suggests that the company is trading at a premium compared to its peers, with LifeVantage Corp. showing a more attractive EV to EBITDA of 8.26.
Despite a one-year return of 6.30%, which is lower than the S&P 500's return of 14.08%, the company's performance over three years at 64.31% is notable but still lags behind the benchmark's 81.19%. Given these factors, Nature's Sunshine Products, Inc. is currently overvalued relative to its peers and market performance.